Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Added to Nasdaq Biotechnology Index

NEW YORK (GenomeWeb News) – Following its semi-annual re-ranking, the Nasdaq Biotechnology Index has added Sequenom to the firms included in the Index.
Sequenom’s shares will start trading as part of the Index on Monday, Nov. 19.
The firm’s shares have more than doubled since mid-September, following the firm’s announcement that it had licensed technology from Harvard University that it will use to develop a nanopore-based sequencing platform that will be faster and cheaper than currently available technologies. Sequenom’s stock closed at $10.10 in Friday trade on the Nasdaq.
Sequenom was one of eight new firms added the Biotech Index, but it was the only non-therapeutics company added. The other seven firms are Beijing Med-Pharm, Cadence Pharmaceuticals, Eurand, Halozyme Therapeutics, Obagi Medical Products, Orexigen Therapeutics, and Theravance.
The seven firms dropped from the Biotech Index as a result of the re-ranking include Avanir Pharmaceuticals, Genta, Hollis-Eden Pharmaceuticals, NeoPharm, Northfield Labs, Oscient Pharmaceuticals, and Pharmacyclics.
Index criteria include listing on the Nasdaq Global Market or Nasdaq Global Select Market, and meeting minimum requirements for market value, average daily share volume, and seasoning as a public company.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.